Dr. Bogdana Schmidt

So in your perfect scenario of this perfect biomarker that I truly am optimistic it'll come. It may not be perfect right away, but we'll have something where we have nothing right now. Do you use ctDNA in your practice right now to make decisions? I do. I do.

Yeah, I think so too. I think the medical oncologists I work with who are phenomenal and I love them and trust them very much, but they have the same struggles that you're experiencing. They actually don't wanna check because they don't know what to do with that information.

Yeah, I think so too. I think the medical oncologists I work with who are phenomenal and I love them and trust them very much, but they have the same struggles that you're experiencing. They actually don't wanna check because they don't know what to do with that information.

Yeah, I think so too. I think the medical oncologists I work with who are phenomenal and I love them and trust them very much, but they have the same struggles that you're experiencing. They actually don't wanna check because they don't know what to do with that information.

And I think the prospective data at InVigor and Modern, like you mentioned, are going to give us that data and hopefully help us figure out how to interpret this so that we have less hesitation to get the data in the first place so that we sort of know what to do with it.

And I think the prospective data at InVigor and Modern, like you mentioned, are going to give us that data and hopefully help us figure out how to interpret this so that we have less hesitation to get the data in the first place so that we sort of know what to do with it.

And I think the prospective data at InVigor and Modern, like you mentioned, are going to give us that data and hopefully help us figure out how to interpret this so that we have less hesitation to get the data in the first place so that we sort of know what to do with it.

So this gets me into my next question, which I wanted to ask after Niagara, and then I wanted to ask after Ambassador, and I figure I just have to ask it now. So the earlier and earlier in the system that we're introducing checkpoints, right? We hope, of course, that all of that works and our patients don't progress and don't develop metastatic disease.

So this gets me into my next question, which I wanted to ask after Niagara, and then I wanted to ask after Ambassador, and I figure I just have to ask it now. So the earlier and earlier in the system that we're introducing checkpoints, right? We hope, of course, that all of that works and our patients don't progress and don't develop metastatic disease.

So this gets me into my next question, which I wanted to ask after Niagara, and then I wanted to ask after Ambassador, and I figure I just have to ask it now. So the earlier and earlier in the system that we're introducing checkpoints, right? We hope, of course, that all of that works and our patients don't progress and don't develop metastatic disease.

And that's why we do all of it, which makes perfect sense. But now that we have really great EV PEMBRO data for metastatic disease, and I know you don't have a crystal ball to tell me for sure how using checkpoint up front will impact that data. But what do you think? Are you worried that it'll make that data look worse? Or do you hope that it'll make it look better because of a priming effect?

And that's why we do all of it, which makes perfect sense. But now that we have really great EV PEMBRO data for metastatic disease, and I know you don't have a crystal ball to tell me for sure how using checkpoint up front will impact that data. But what do you think? Are you worried that it'll make that data look worse? Or do you hope that it'll make it look better because of a priming effect?

And that's why we do all of it, which makes perfect sense. But now that we have really great EV PEMBRO data for metastatic disease, and I know you don't have a crystal ball to tell me for sure how using checkpoint up front will impact that data. But what do you think? Are you worried that it'll make that data look worse? Or do you hope that it'll make it look better because of a priming effect?

Thank you. And like I said, this is something that we're all going to ask more and more as we basically have more of these patients, right? Right now, these are all patients that have just been on trial. And so we'll be following them closely. But as we start to make these decisions, hopefully we'll get some more real world. evidence in this space.

Thank you. And like I said, this is something that we're all going to ask more and more as we basically have more of these patients, right? Right now, these are all patients that have just been on trial. And so we'll be following them closely. But as we start to make these decisions, hopefully we'll get some more real world. evidence in this space.

Thank you. And like I said, this is something that we're all going to ask more and more as we basically have more of these patients, right? Right now, these are all patients that have just been on trial. And so we'll be following them closely. But as we start to make these decisions, hopefully we'll get some more real world. evidence in this space.

So we've spoken about the more advanced bladder cancer setting, the muscle invasive, kind of how to make these decisions. I do want to talk a little bit, just for the surgeons in the audience, about some of the more surgical trials, the Sunrise trials, starting with Sunrise. four, which was the muscle invasive trial with citralumab and TAR200.

So we've spoken about the more advanced bladder cancer setting, the muscle invasive, kind of how to make these decisions. I do want to talk a little bit, just for the surgeons in the audience, about some of the more surgical trials, the Sunrise trials, starting with Sunrise. four, which was the muscle invasive trial with citralumab and TAR200.

So we've spoken about the more advanced bladder cancer setting, the muscle invasive, kind of how to make these decisions. I do want to talk a little bit, just for the surgeons in the audience, about some of the more surgical trials, the Sunrise trials, starting with Sunrise. four, which was the muscle invasive trial with citralumab and TAR200.

And I think this one points a really great point on what we mentioned earlier with the patients who refuse cisplatin. In this set of patients, there are just 60-something percent of patients that enrolled on this trial We're cisplatinum eligible, but refusing cisplatinum.